What OPPS billing guidelines should be followed when commercially available products are mixed together to facilitate their concurrent administration?


Under the outpatient prospective payment system (OPPS), if commercially available products are being mixed together to facilitate their concurrent administration, the hospital should report (by HCPCS code) the quantity of each product used in the patient’s care. Alternatively, if the hospital is compounding drugs that are not a mixture of commercially available products, but are a different product that has no applicable HCPCS code, then the hospital should report an appropriate unlisted drug code (J9999 or J3490).

In these situations, it is not appropriate to bill HCPCS code C9399 (unclassified drug or biological), which is for new drugs and biologicals approved by the Food & Drug Administration but a specific HCPCS code has not been assigned yet.


CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.